An active, but no longer recruiting phase I clinical trial is investigation PRT811, a PRMT5 inhibitor, but again without a glioblastoma focus as the trial is treating all high grade gliomas (clinicaltrials.gov). Here, PRMT5 is linked to glioblastoma.